Effects of pyridostigmine bromide on human thermoregulation during cold water immersion.
This study examined the effects of an oral 30-mg dose of pyridostigmine bromide (PYR) on thermoregulatory and physiological responses of men undergoing cold stress. Six men were immersed in cold water (20 degrees C) for up to 180 min on two occasions, once each 2 h after ingestion of PYR and 2 h after ingestion of a placebo. With PRY, erythrocyte cholinesterase inhibition was 33 +/- 12% (SD) 110 min postingestion (10 min preimmersion) and 30 +/- 7% at termination of exposure (mean 117 min). Percent cholinesterase inhibition was significantly related to lean body mass (r = -0.91, P less than 0.01). Abdominal discomfort caused termination in three of six PYR experiments but in none of the control experiments (mean exposure time 142 min). During immersion, metabolic rate, ventilatory volume, and respiratory rate increased significantly (P less than 0.05) over preimmersion levels and metabolic rate increased with duration of immersion (P less than 0.01) in both treatment but did not differ between conditions. PYR had no significant effect on rectal temperature, mean body temperature, thermal sensations, heart rate, plasma cortisol, or change in plasma volume. It was concluded that a 30-mg dose of PYR does not increase an individual's susceptibility to hypothermia during cold water immersion; however, in combination with cold stress, PYR may result in marked abdominal cramping and limit cold tolerance.
Prusaczyk
W K
WK
US Army Research Institute of Environmental Medicine, Natick, Massachusetts 10760-5007.
Sawka
M N
MN
D000328:Adult; D001833:Body Temperature Regulation / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D003080:Cold Temperature; D004912:Erythrocytes / Q000201:enzymology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007101:Immersion; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D010465:Perception / Q000187:drug effects; D011729:Pyridostigmine Bromide / Q000494:pharmacology*; D014661:Vasoconstriction / Q000187:drug effects
D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide